MKMonika Kraus

Monika Kraus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monika Kraus has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    #consented – A semantic consent code to facilitate consistent documentation and implementation of consent in collaborative medical research

    by Martin Bialke, Christopher Hampf, Arne Blumentritt, Frank-Michael Moser, Stefan Lang, Aileen Stehn, Ellen Sargsyan, Wolfgang Hoffmann, Monika Kraus


  • Open Access

    Prevalence of infectious diseases, immunity to vaccine-preventable diseases and chronic medical conditions among Ukrainian refugees in Germany – A cross sectional study from the German Network University Medicine (NUM)

    by Folke Brinkmann, Anette Friedrichs, Georg Mn Behrens, Pia Behrens, Reinhard Berner, Amke Caliebe, Claudia M. Denkinger, Katharina Giesbrecht, Alexander Gussew, Anna Theresa Hoffmann, et al.


  • Open Access

    The Importance of Being FAIR and FAST – The Clinical Epidemiology and Study Platform of the German Network University Medicine (NUKLEUS)

    by Dagmar Krefting, Gabi Anton, Irina Chaplinskaya-Sobol, Sabine Hanss, Wolfgang Hoffmann, Sina M. Hopff, Monika Kraus, Roberto Lorbeer, Bettina Lorenz-Depiereux, Thomas Illig, et al.

    The COVID-19 pandemic has urged the need to set up, conduct and analyze high-quality epidemiological studies within a very short time-scale to provide timely evidence on influential factors on the pandemic, e.g. COVID-19 severity and disease course. The comprehensive research infrastructure developed to run the German National Pandemic Cohort Network within the Network University Medicine is now maintained within a generic clinical epidemiology and study platform NUKLEUS. It is operated and subsequently extended to allow efficient joint planning, execution and evaluation of clinical and clinical-epidemiological studies. We aim to provide high-quality biomedical data and biospecimens and make its results widely available to the scientific community by implementing findability, accessibility, interoperability and reusability - i.e. following the FAIR guiding principles. Thus, NUKLEUS might serve as role model for FAIR and fast implementation of clinical epidemiological studies within the setting of University Medical Centers and beyond.


  • Open Access

    The DZHK research platform: maximisation of scientific value by enabling access to health data and biological samples collected in cardiovascular clinical studies

    by Julia Hoffmann, Sabine Hanß, Monika Kraus, Jens Schaller, Christian Schäfer, Dana Stahl, Stefan D. Anker, Gabriele Anton, Thomas Bahls, Stefan Blankenberg, et al.

    The German Centre for Cardiovascular Research (DZHK) is one of the German Centres for Health Research and aims to conduct early and guideline-relevant studies to develop new therapies and diagnostics that impact the lives of people with cardiovascular disease. Therefore, DZHK members designed a collaboratively organised and integrated research platform connecting all sites and partners. The overarching objectives of the research platform are the standardisation of prospective data and biological sample collections among all studies and the development of a sustainable centrally standardised storage in compliance with general legal regulations and the FAIR principles. The main elements of the DZHK infrastructure are web-based and central units for data management, LIMS, IDMS, and transfer office, embedded in a framework consisting of the DZHK Use and Access Policy, and the Ethics and Data Protection Concept. This framework is characterised by a modular design allowing a high standardisation across all studies. For studies that require even tighter criteria additional quality levels are defined. In addition, the Public Open Data strategy is an important focus of DZHK. The DZHK operates as one legal entity holding all rights of data and biological sample usage, according to the DZHK Use and Access Policy. All DZHK studies collect a basic set of data and biosamples, accompanied by specific clinical and imaging data and biobanking. The DZHK infrastructure was constructed by scientists with the focus on the needs of scientists conducting clinical studies. Through this, the DZHK enables the interdisciplinary and multiple use of data and biological samples by scientists inside and outside the DZHK. So far, 27 DZHK studies recruited well over 11,200 participants suffering from major cardiovascular disorders such as myocardial infarction or heart failure. Currently, data and samples of five DZHK studies of the DZHK Heart Bank can be applied for.


  • Open Access

    The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics

    by Maximilian Schons, Lisa Pilgram, Jens-Peter Reese, Melanie Stecher, Gabriele Anton, Katharina S. Appel, Thomas Bahmer, Alexander Bartschke, Carla Bellinghausen, Inga Bernemann, et al.

    The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON’s goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36–62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON’s design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities. Trial registration https://clinicaltrials.gov/ct2/show/NCT04768998 . https://clinicaltrials.gov/ct2/show/NCT04747366 . https://clinicaltrials.gov/ct2/show/NCT04679584


  • Open Access

    Studienübergreifende Harmonisierung datenschutzrechtlicher und ethischer Gesichtspunkte in Patientenunterlagen: Eine Praxisanalyse

    by Monika Kraus, Matthias Nauck, Dana Stahl, Arne Blumentritt, Gabriele Anton, H.-Erich Wichmann, Annette Peters

    Zusammenfassung: Im Rahmen des Deutschen Zentrums für Herz-Kreislauf-Forschung e. V. (DZHK) wurden die klinische Forschungsplattform des DZHK für die Erhebung von standardisierten Daten und Bioproben aus DZHK-finanzierten klinischen Studien sowie ein Antrags- und Zugangsprozess unter Einbeziehung eines Use and Access Komitees für weitere medizinische Forschungsprojekte aufgebaut.Die Sammlung dieser Forschungsressourcen erfolgt auf Basis eines DZHK-weit harmonisierten Broad Consent. Entsprechend ergänzte Patienteninformations- und Einwilligungsunterlagen der DZHK-Studien wurden seit 2013 bereits von über 50 Ethikkommissionen deutschlandweit positiv begutachtet. Inhalte von 43 Ethikvoten aus den Jahren 2017 und 2018 wurden ausgewertet sowie eine Ist-Analyse (Q4/2019) der Anzahl beteiligter Studienzentren und der Anzahl verwalteter Einwilligungsversionen durchgeführt.Die Auswertungen spiegeln die erhöhten Herausforderungen wider, die sich seit verbindlich werden der EU-Datenschutzgrundverordnung (EU-DSGVO) im Mai 2018 ergaben. Durch Forderungen und Änderungswünsche einzelner Ethikkommissionen werden derzeit (Q4/2019) 75 unterschiedliche, die Daten- und Biomaterialsammlung betreffende Patienteninformations- und Einwilligungsunterlagen für 19 klinische Studien verwaltet.Trotz eines, im Verhältnis zur Anzahl der teilnehmenden Studien und Studienzentren, hohen Harmonisierungsgrades bestehen aufgrund von Forderungen aus den Ethikvoten deutliche Unterschiede in den Formulierungen der DZHK-Patientenunterlagen, die u. a. kritische Aspekte wie Speicherzeitbegrenzung, Widerruf und Weitergabe von Daten für die Forschung betreffen. Der Artikel soll die Schwierigkeiten, mit denen wir und andere übergreifende Forschungsverbünde im Alltagsbetrieb bei Ethikeinreichungen konfrontiert werden, strukturiert darlegen und den Umgang des DZHK e. V. damit beschreiben um Wünsche für eine zukünftige Vorgehensweise zu formulieren.